

foot-and-mouth disease vaccination-induced injection site lesions in slaughtered pigs and its causal relationship. *J Prev Vet Med* 39: 153-156.

- [3] Valtulini S, Macchi C, Ballanti P, Cherey Y, Laval A, Theaker JM, Bak M, Ferretti E, Morvan H. 2005. Aluminiumhydroxide-induced granulomas in pigs. *Vaccine* 23: 3999-4004.

P-102

Application of thromboelastography for the prediction of mortality for intensive care patients

Na-Yon Kim¹, Yeseul Yang¹, Sumin Ji¹, Sung-Hyun Hwang¹, Hong-Seok Lee¹, Myung-Chul Kim¹, Yongbaek Kim²

¹Laboratory of Clinical Pathology, BK21 PLUS Program for Creative Veterinary Science Research, College of Veterinary Medicine, Seoul National University, Seoul, The Republic of Korea 08826; ²Laboratory of Clinical Pathology, Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul, The Republic of Korea 08826

Introduction: One of the leading causes of death for intensive care patients is hemostatic dysfunction including disseminated intravascular coagulopathy and bleeding. Clinicopathological exams to assess the function of coagulative system are PT, aPTT, and D-dimer. However, abnormal status of the coagulative system cannot be properly determined by either PT or aPTT because these tests are negative until fall below approximately 30% of normal value. Thromboelastography provides more global test that help facilitate accurate evaluation of hemorrhagic or thrombotic risks. Therefore, the present study was performed to evaluate the thromboelastography for the prediction of mortality in intensive care patients.

Materials and Methods: The study population was divided into two groups. Group I involved stable canine patients with potential hypercoagulable diseases including cancer, pancreatitis, pyometra, and hyperadrenocorticism. Group II enrolled the patients with multiple organ dysfunction syndrome or the patients who died within 72 hours of admission. Whole blood was collected from jugular vein. Blood sample in EDTA tube was subjected to complete blood count by Advia 2120i (Siemens Healthcare, Erlangen, Germany). To obtain a dilution of whole blood to sodium citrate of 9:1, 3.2% sodium citrate tube was used. PT, and aPTT were measured using Coag Dx Analyzer (IDEXX Laboratories Inc, ME, USA). Thromboelastography was performed by TEG 5000 Thromboelastograph Hemostasis Analyzer System (Haemonetics Corporation, MA, USA). In some patients, D-dimer was also measured after centrifugation.

Results: Thirty-six dogs presented to SNU-VMIH were enrolled in the present study. Group I included 30 patients, and Group II had 6 patients. PT had no significant difference between Group I and II, however, aPTT level was significantly increased in Group II (mean: 100.7 ± 6.2

seconds; range: 81-126 seconds) compared to Group I (mean: 87.2 ± 2.0 seconds; range: 73-116 seconds) ($P < .05$). MPV value was also significantly increased in Group II patients (mean: 12.02 ± 0.92 minutes; range: 9.0-15.1 minutes) compared to Group I (mean: 10.81 ± 0.63 minutes; range: 7.0-21.9 minutes). Among thromboelastography results, the R value demonstrated a significant difference between Group I and II ($P < .05$). Group II dogs had a significantly increased R value (mean: 8.63 ± 1.36 minutes; range: 4.6-14.2 minutes) than that in Group I (mean: 5.71 ± 2.48 minutes; range: 0.8 ± 10.3 minutes) ($P < .05$).

Conclusions: This study demonstrated that R value, representing the initial formation of the clot, was the only TEG marker predictive of mortality. Increase in R value was associated with an increased risk of death. Therefore, R value could be used as an indicator of prognosis of patients associated with high mortality. However due to small population, further studies may be warranted to determine the significance of thromboelastography abnormalities.

P-103

Successful Generation of a Complete Recombinant H9N2 Avian Influenza Virus by modifying Hoffmann's Reverse Genetics Vector System

Se-Hee An¹, Chung-Young Lee¹, Jun-Goo Choi³, Youn-Jeong Lee³, Jae-Hong Kim¹, Hyuk-Joon Kwon²

¹Laboratory of Avian Diseases, College of Veterinary Medicine, Seoul National University; ²Department of Farm Animal Medicine, College of Veterinary Medicine, Seoul National University; ³Animal and Plant Quarantine Agency, Korea

Introduction: Reverse genetics system of influenza A virus (IAV) has advanced to the bidirectional 8-plasmid system which has human promoters of polymerase I and II, resulting in synthesis of viral RNA (vRNA) and mRNA from one template (Hoffmann *et al.*, 2001). This system is very efficient for recombinant virus generation due to transfection of only 8 plasmids encoding each genome segment of IAV into cell. Because all IAVs have conserved terminal sequences in both ends of vRNA, universal primer set containing conserved sequence and segment specific sequence can be used to cloning genome of diverse subtype viruses. Through this method, various subtypes of avian IAVs (AIVs) have been generated easily as reassortants with six genomes of high yielding A/PR/8/34 (PR8) virus. However, there was a limit that recombinant viruses having whole genome of some AIVs are very difficult to rescue. Recently we found some polymerase genes were not adapted to mammals and could not support efficient virus replication in mammalian cells (Kim *et al.*, 2014; Lee *et al.*, 2017). Furthermore, we found the constellation of the fourth nucleotide at the 3' end of viral genome (C4, weak promoter and U4, strong promoter) were important for

efficient virus replication and mammalian pathogenicity (Lee et al, 2017). The polymerase genomes (PB2, PB1 and PA) of Hoffmann's vector system possess the weak promoter, C4. Therefore, in this study we demonstrated the hypothesis that promoter change from C4 to U4 in polymerase genomes can generate a complete recombinant H9N2 AIV.

Materials and Methods: Each genome of A/chicken/Korea/01310/2001 (H9N2) (01310) virus CE2 and CE20 was cloned into the bi-directional pHW2000 vector. 4th nucleotide in Non-coding region (NCR) of polymerase genes were mutated from C to U by site-directed mutagenesis kit. Recombinant 01310 viruses (r01310) were regenerated by transfecting 8 plasmids to 293T cell. The culture medium was injected into 10-day-old SPF embryonated chicken eggs via allantoic fluid cavity and harvested allantoic fluid is tested by HA assay using 1% chicken RBC.

Results: In contrast to polymerase genes with C4 complete recombinant virus, r01310 was generated successfully by using polymerase genes with U4. But, when PA plasmid was solely mutated into U4, r01310 was not rescued.

Conclusions: Changing weak (C4) to strong (U4) promoters of polymerase genomes of Hoffmann's vector system was enough to generate a complete recombinant AIV, r01310, and our method maybe useful to generate wild and mutant AIVs for studies on genotype-phenotype correlation.

References

- [1] Hoffmann, E., et al. "Universal primer set for the full-length amplification of all influenza A viruses." *Archives of virology* 146.12 (2001): 2275-2289.
- [2] Kim, I.H., et al. Effect of different polymerases of avian influenza viruses on the growth and pathogenicity of A/Puerto Rico/8/1934 (H1N1)-derived reassorted viruses. *Veterinary Microbiology* 168(2014): 41-49
- [3] Lee, C.Y., et al. Effect of the fourth nucleotide at the 3' end of neuraminidase and matrix viral genomic RNA on the pathogenicity of influenza virus A/PR/8/34. *J Vet Sci* 2017, 18(S1) (2017): 307-313.
- [4] Lee, C.Y., et al. Prerequisites for the acquisition of mammalian pathogenicity by influenza A virus with a prototypic avian PB2 gene. *Scientific Reports*.7(2017): 10205.

P-104

Minimum Infectious Dose Determination of the K40/09 Infectious bronchitis Virus vaccine candidate strain by spray administration

Junyoung Kim¹, Hana Youn², Wootack Hong¹, Hyosun Ju², Kyujik Kim¹, Seungsu Yuk¹, Junghoon Kwon¹, Jinyong Noh¹, Jehyeon Jung¹, Sol Jeong¹, Yujik Kim¹, Junbeom Kim¹, Jiho Lee¹, Sangwon Lee¹, Joong Bok Lee¹, Seungyong Park¹, Insoo Choi¹, Changseon Song^{2*}

¹Avian Disease Laboratory, College of Veterinary Medicine,

Konkuk University; ²KCAV Co, Ltd

Introduction: Infectious bronchitis virus (IBV) causes an acute and highly contagious viral disease of chickens that is characterized by respiratory signs, nephritis, and reduced egg reproduction. Current IBV vaccine strains do not cross-protect against new viral strains because of the extensive genetic diversity and high mutation rate of IBV. Therefore, the best protective effect that can be achieved would be only against strains of the same serotype or genotype. In our previous study, the natural recombinant nephropathogenic IBV strain K40/09 was heat-adapted as a live attenuated vaccine and showed significantly high levels of immunogenicity and protective ability against many different types of IBV.

In the field, IBV vaccine is delivered by mass applications but mostly delivered via hatchery spray cabinet and eye drop administration. So we sought to determine the minimum infectious dose of K40/09 IBV vaccine candidate strain by spray administration in one-day-old chick.

Materials and Methods: One-day-old specific pathogen free (SPF) chicks were divided into 9 groups. 4 groups vaccinated with attenuated K40/09 vaccine candidate strain (CE60) either a 10^{1.5}, 10^{2.5}, 10^{3.5}, 10^{4.5} EID₅₀ dose and 3 control groups were vaccinated with commercial H120 IBV vaccine as 0.01x, 0.1x, 1x of manufacturer's recommend dose using a fine-spray cabinet (Three Shine, droplet size = 50 μm), whereas the other 2 groups were kept as non-immunized controls. Three weeks after vaccination, serum samples were collected and level of IBV-specific antibodies were determined by enzyme-linked immunosorbent assay (ELISA). After that all of the birds were challenged intraocularly with 10^{4.5} EID₅₀ of each homologous IBV strain K40/09 and M41, respectively. Five days after challenge, the challenge virus was re-isolated from the trachea and kidney of the birds by inoculating 9 to 11 day old embryonated SPF chicken eggs to evaluate the protective efficacy of vaccines.

Results: Group of chickens immunized with K40/09 showed protection of the respiratory tract and kidney when vaccinated over 10^{2.5} EID₅₀ dose. And ELISA titer also showed positive over 10^{2.5} EID₅₀ dose.

Group of chickens immunized with H120 vaccine showed protection of the respiratory tract and kidney when vaccinated over 0.1x of manufacturer's recommend dose but ELISA titer was low at all dose. Compared with the non-vaccinated control group, and there were no clinical sign between vaccination groups and control group showed 100% re-isolation of challenge strain in the respiratory tract and kidney.

Conclusions: In summary, we have demonstrated the minimum infectious dose for the attenuated K40/09 infectious bronchitis virus vaccine candidate strain by spray administration is 10^{2.5} EID₅₀. This study will be helpful of developing future vaccination protocols and implementing them properly.